HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Commissioner Admonishes Health Care Stakeholders To Know Agency Better, Help More

Executive Summary

Califf was candid during Science Board meeting about agency’s limits, such as disseminating accurate information in response to rampant misinformation during COVID-19 pandemic. “We need to call out people who are outside the FDA … because this vast universe of information out there is way bigger than we can handle on our own,” he said.

You may also be interested in...



Democrats, Republicans Agree US FDA’s Food Safety Programs Need Help, Disagree On How

Democrats on Oversight and Investigation Subcommittee support increasing funding for FDA’s regulation of food product manufacturing and marketing, but Republicans advise Commissioner Robert Califf the agency should do more with authority it already has and without adding to its budget.

OTC Naloxone May Get Another Push From US FDA As Agency Prepares Novel Switch Proposed Rule

Financial model isn't adequate currently, FDA Commissioner Robert Califf says, and agency may make regulatory changes to motivate sponsors.

Nicotine Gummies Sold For Smoking Cessation Doused Under US FDA Tobacco Regulations

FDA says warning to VPR Brands could be its first move to reign in sales of nicotine gummies. Statements on brand’s site could indicate sales of nicotine gummies for smoking cessation are on the rise even though the claim isn’t approved.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel